-
Safeguard Scientifics Realizes $145.4 Million in Aggregate Cash Proceeds from Shires Acquisition of Advanced BioHealing
Tuesday, June 28, 2011 - 9:40am | 179Safeguard Scientifics (NYSE: SFE) today announced that its aggregate cash proceeds from the completed sale of life sciences partner company Advanced BioHealing to Shire plc (NASDAQ: SHPGY) are $145.4 million. In addition, $7.3 million will be held in escrow pending the expiration of an escrow...
-
Deutsche Bank Maintains Buy Rating on Medicis
Tuesday, June 28, 2011 - 8:14am | 84Deutsche Bank is maintaining its Buy rating on Medicis Pharmaceutical (NYSE: MRX). “The outlook for Medicis' flagship Solodyn franchise has improved significantly – based on a strong switch thus far to the ‘new' protected doses and the key Q1 settlement with Teva,” Deutsche Bank writes. “Hence, we...
-
Benzingas Top Pre-Market NASDAQ Losers
Tuesday, June 28, 2011 - 8:11am | 111Swisher Hygiene Inc (NASDAQ: SWSH) dipped 4.90% to $5.24 in the pre-market session. SWSH acquired Prinova Co Inc. Icagen Inc (NASDAQ: ICGN) dropped 1.90% to $6.21 in the pre-market trading. Pfizer Inc (NYSE: PFE) reported that it is considering a strategic transaction with Icagen. ASML Holding...
-
AmDerma Pharmaceuticals Exercises Option to License Rights to Oculus Innovative Sciences Acne Drug Candidate
Tuesday, June 28, 2011 - 8:09am | 60Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) announced today that AmDerma Pharmaceuticals, the parent company of Quinnova Pharmaceuticals, Inc., an alliance member of Amneal Enterprises, has exercised its option to license rights to Oculus' Microcyn-based acne drug candidate. AmDerma and Oculus...
-
Hi-Tech Pharmacal Acquires Rights to Branded Products to be Promoted by their ECR Pharmaceuticals Subsidiary for $3.6M
Tuesday, June 28, 2011 - 8:06am | 84Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK), a specialty pharmaceuticals company, announced today that they acquired marketing and distribution rights to several unique branded products for the treatment of pain from Atley Pharmaceuticals. Some products are approved and some are pending approval...
-
Pfizer Files With The FDA For Review Of Axitinib
Tuesday, June 28, 2011 - 8:01am | 73Pfizer (PFE) announced today that the U.S. Food and Drug Administration has accepted Pfizer's filing for standard review of axitinib for patients with advanced renal cell carcinoma. This submission was based on Phase 3 data from the AXIS 1032 trial, comparing axitinib with sorafenib in patients...
-
Deutsche Bank Updates 6/28
Tuesday, June 28, 2011 - 7:38am | 451Deutsche Bank made a number of updates in a research report published today. Flowers Foods (NYSE: FLO) had its rating reinstated at Hold. At the same time, its price target was reduced from $25 to $20. On Monday, Flowers added 0.25% to its value to end the day at $21.74. Medicis Pharmaceutical (...
-
Bank Of America Raises Price Target On Forest Labs To $45
Tuesday, June 28, 2011 - 7:33am | 146According to Bank of America, Forest Labs (NYSE: FRX) price target is raised to $45. Bank of America said that it is raising its PO to $45 (from $40) to reflect value for Namenda XR, which it assumes preserves some value for the franchise post-generic Namenda, as well as some additional cost...
-
A Peek Into The Market Before The Trading Starts
Tuesday, June 28, 2011 - 7:22am | 391Pre-open movers US stock futures are slightly lower this morning. Greek Parliament is scheduled to vote Wednesday on the EUR28.4 billion, five-year austerity package. Futures on the Dow Jones Industrial Average dropped 17 points to 11,973.00 and futures on the S&P 500 stock index fell 2.60...
-
UPS and Merck Expand Their Distribution and Logistics Agreement
Tuesday, June 28, 2011 - 7:01am | 64UPS (NYSE: UPS) and Merck (NYSE: MRK), today announced that the companies have significantly broadened their existing distribution and logistics agreement to include aspects of Merck's global supply chain around the world. UPS currently manages the distribution, warehousing and transportation of...
-
Teva Pharmaceutical: Generic value
Monday, June 27, 2011 - 8:00pm | 123by J. Royden Ward, editor Cabot Benjamin Graham Value Letter The performance of Teva Pharmaceutical Industries (TEVA) has been disappointing for quite some time now. Investors have avoided TEVA because its largest selling drug, Copaxone, which treats multiple sclerosis (MS), will meet some new...
-
Icagen
Monday, June 27, 2011 - 6:49pm | 33Icagen (ICGN), a tiny biotech, leapt 164% to 6.33 after Pfizer (PFE) revealed in federal documents that it is evaluating a possible purchase of the company. It currently owns 14.2% of Icagen. Pfizer edged up 0.5% to 20.17.
-
Stocks Shrug Off Greece, Deficit Uncertainty
Monday, June 27, 2011 - 1:35pm | 149(TheStreet) -- Technology, financials and conglomerates were leading stocks higher as austerity plan negotiations in Greece and deficit reduction talks in Washington heat up. The Dow Jones Industrial Average was up by 105 points, or 0.9%, at 12,040. The S&P 500 was higher by 10 points, or 0.8...
-
NASDAQ Stocks Hitting 52-Week Lows
Monday, June 27, 2011 - 11:40am | 125Zhongpin Inc (NASDAQ: HOGS) shares fell 12.02% to create a new 52-week low of $9.66. HOGS is scheduled to meet with institutional investors at the Oppenheimer 11th Annual Consumer Conference in Boston on June 28 and 29. Pozen Inc (NASDAQ: POZN) shares dropped 0.69% to create a new 52-week low of $...
-
NASDAQ Stocks Hitting 52-Week Highs
Monday, June 27, 2011 - 11:34am | 140Icagen Inc (NASDAQ: ICGN) shares rose 129.18% to create a new 52-week high of $5.50. Pfizer Inc (NYSE: PFE) reported that it is considering a strategic transaction with Icagen. Cornerstone Therapeutics Inc (NASDAQ: CRTX) shares gained 7.01% to create a new 52-week high of $8.43. CRTX's trailing-...